Navigation Links
Idenix Pharmaceuticals Reports First Quarter Financial Results
Date:4/30/2009

Total operating expenses 17,326 23,844 ------ ------ Loss from operations (13,315) (21,800) Other income (expense), net (49) 939 ---- --- Loss before income taxes (13,364) (20,861) Income tax benefit 438 401 --- --- Net loss $(12,926) $(20,460) ========= ========= Basic and diluted net loss per share: ($0.23) ($0.36) ======= ======= Shares used in calculation of basic and diluted net loss per share: 56,940 56,274 ====== ====== (1) Stock-based compensation expenses included in operating expenses amounted to approximately: Research and development $439 $660 General and administrative 817 880

                     IDENIX PHARMACEUTICALS, INC.

                CONDENSED CONSOLIDATED BALANCE SHEETS

                          (IN THOUSANDS)

                            (UNAUDITED)

                                                      March 31, December 31,
                                                          2009       2008

    ASSETS
    Cash and cash equivalents                           $62,567    $41,509
    Marketable securities                                     -      1,424
    Receivables from related party                          81
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Long Beach, CA (PRWEB) December 17, 2014 ... Technology, Inc. to provide a larger packaged waste water ... district in King Abdullah Economic City (KAEC). Two years ... for EMAAR’s Jeddah Gate Development, serving two residential towers ... plant capacity is over a quarter million gallons per ...
(Date:12/17/2014)... 17, 2014 Xeno Diagnostics has ... its most recent COLA inspection. Xeno has met ... national healthcare accreditation organization. Accreditation is earned only ... in day-to-day operations, demonstrate continued accuracy in the ... on-site laboratory survey. , While the ...
(Date:12/17/2014)... Audacity, a leading California-based health and ... the Huntsworth Health Group, is proud to announce the ... her role, Gonzales will serve as Senior Vice President ... to welcome a talent of Jamie’s caliber to the ... “She is a proven healthcare innovation leader and brand ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... promotions as well as changes to Martine Rothblatt ... Promotions United Therapeutics announced the promotion ... Co-Chief Executive Officer and David Zaccardelli , Pharm.D. ... connection with these promotions, Dr. Rothblatt,s title will change ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... Pa., Nov. 5 VWR Funding, Inc. (formerly CDRV,Investors, Inc.) the parent company of ... call on Thursday,November 15th to discuss its financial results for the quarter ended September,30, ... Ballbach, Chairman, President and CEO ... ...
... - Revenue Increased 61% Compared to 3Q06 to $43.5 Million in 3Q07 -,- ... ... Diluted Share - - Company Provides ... American Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading manufacturer and distributor of,plant-based ...
... SAN FRANCISCO, Calif., Nov. 5 Exelixis,Inc. (Nasdaq: ... the third quarter,ended September 30, 2007. Revenues ... $26.8 million,compared to $23.5 million for the comparable ... to 2007 was primarily due to revenue recognition,associated ...
Cached Biology Technology:VWR Funding, Inc. to Hold Third Quarter 2007 Financial Results Conference Call 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 8Exelixis Announces Third Quarter 2007 Financial Results and Business Update 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 3Exelixis Announces Third Quarter 2007 Financial Results and Business Update 4Exelixis Announces Third Quarter 2007 Financial Results and Business Update 5Exelixis Announces Third Quarter 2007 Financial Results and Business Update 6Exelixis Announces Third Quarter 2007 Financial Results and Business Update 7Exelixis Announces Third Quarter 2007 Financial Results and Business Update 8
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... supplements during pregnancy is not only safe for mother and ... to results of a randomized controlled study to be presented ... British Columbia, Canada. In the 1950s and ,60s, ... according to Carol L. Wagner, MD, lead author of the ...
... 2010) Natural S-equol, a novel soy germ-based compound, ... flushes in the dietary supplement SE5-OH, which is under ... efficacy data from studies using an animal model presented ... SE5-OH is in advanced studies in menopausal women, and ...
... , Using DNA samples and images from Earth-orbiting ... Society, the American Museum of Natural History, and ... franciscanaa poorly known coastal dolphin species of eastern ... conserve them. The study, one of ...
Cached Biology News:Researchers recommend pregnant women take 4,000 IU vitamin D a day 2Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 2Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 3Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 4Natural S-Equol suggested as critical component in SE5-OH for reducing menopausal hot flushes 5Satellites, DNA and dolphins 2Satellites, DNA and dolphins 3Satellites, DNA and dolphins 4